Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover access to tremelimumab for prior-study participants
2008-000989-23Phase 2Unknown
- Sponsor
- AstraZeneca
- Start
- Jun 2008
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tremelimumab in melanoma, Nonhematologic neoplasms, carcinoma and 1 more, sponsored by AstraZeneca. Status: unknown.
02
Drugs
tremelimumab
03
Conditions
melanomaNonhematologic neoplasmscarcinomacancer
Beyond the preview
Go deeper on 2008-000989-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000989-23.